Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Evatanepag is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing.
Description | Evatanepag is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. |
In vitro | CP-533536 is a potent and selective EP2agonist. CP-533536 shows the ability to heal fractures when administered locally as a single dose in rat models of fracture healing s excellent in vitro potency and it also displays against EP2 and selectivity against a broad panel of other targets. |
Synonyms | CP-533536 free acid |
Molecular Weight | 468.57 |
Formula | C25H28N2O5S |
CAS No. | 223488-57-1 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 32 mg/mL (68.29 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Evatanepag 223488-57-1 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor HDM asthma CP533536 mast cell CP-533536 CP-533536 free acid CP 533536 bone Inhibitor Fracture healing allergy inflammation inhibit inhibitor